Press Releases
Brinks Gilson & Lione Shareholder Jeff Nichols Presents on IPR Best Practices at ACI Life Sciences Patent Summit
February 02, 2017

CHICAGO—Jeff Nichols, a shareholder and patent litigator at intellectual property law firm Brinks Gilson & Lione, will be a featured speaker at ACI’s 15th Advanced Summit on Life Sciences Patents on February 28, 2017 in New York.

Nichols will be a panelist for "Tackling the Offensive and Defensive Sides of Inter Partes Reviews," an overview of best practices for protecting patent portfolios and challenging competitors at the Patent Trial and Appeal Board (PTAB). The panel will review recent decisions to uncover effective uses of the inter partes review process and best practices for appearing before the PTAB, including avoiding procedural pitfalls such as timing and page-limit requirements.

Nichols has extensive experience in patent litigation, particularly in the biotechnology and pharmaceutical industries. He frequently speaks on patent litigation and post-grant proceedings, and is an adjunct professor at The John Marshall Law School. Nichols is co-chair of Brinks’ biotechnology and pharmaceutical practice group, and previously led the firm's litigation practice group.

Brinks is an associate sponsor of ACI’s 15th Advanced Summit on Life Sciences Patents. The conference offers a forum for members of the life sciences industry to learn about strategies for protecting their innovations in areas such as DNA sequencing, gene therapies, and diagnostics.

More information is at

Brinks Gilson & Lione

Celebrating its centennial year in 2017, Brinks Gilson & Lione is one of the largest intellectual property law firms in the US, and helps clients around the world to protect and enforce their intellectual property rights. Our more than 140 lawyers, patent agents and scientific advisors assist clients in all aspects of patent, trademark, unfair competition, trade secret, and copyright law. Brinks attorneys provide informed counsel with respect to innovations in a range of complex and valuable technologies, including pharmaceuticals, chemicals, bioengineering, industrial manufacturing, electronics and software, and medical devices. More information is at

Forward Thinkers